Shenzhen Kangtai Biological Products Launches Phase I Trial for Infant Influenza Vaccine
China‑based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with...
SHE: 300601
Shenzhen Kangtai Secures 530 Million Yuan Technology Transfer for Klebsiella Pneumoniae Vaccine
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) today announced the signing of a technology‑transfer...
Shenzhen Kangtai Receives NMPA Approval for Sabin‑Strain Inactivated Polio Vaccine
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced today that the China National Medical...
Kangtai Biological Gains NMPA Approval for Trivalent Influenza Vaccine Clinical Trial
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that it has received approval from...
Kangtai Biological’s Pentavalent Rotavirus Vaccine Enters Phase III Trials
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) announced the enrollment of the first patient...
Shenzhen Kangtai Partners with AstraZeneca to Establish Vaccine JV in Beijing
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has formed a vaccine-focused partnership with...
Shenzhen Kangtai Halts COVID-19 Vaccine Development Amid Market Shifts
Shenzhen based biopharmaceutical company Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the...
Shenzhen Kangtai Begins Phase I Clinical Trial for 20-Valent Pneumococcal Vaccine
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the enrollment of the...
Kangtai Biological Receives NMPA Approval for 20-Valent Pneumococcal Vaccine Clinical Trial
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading biopharmaceutical company in China, has...
Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a prominent biopharmaceutical company based in China,...
Kangtai Biological Products Co., Ltd. Expands Vaccine Access in South Asia with Bangladesh Deal
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a Chinese biopharmaceutical firm, has announced the...
Kangtai Biological Partners with Bahrain Pharma Firm on Strategic Vaccine Production Agreement
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a prominent player in China’s biotechnology sector,...
Kangtai Biological Partners with Gennvax Egypt to Commercialize 13-Valent Pneumococcal Vaccine
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a Chinese biopharmaceutical company, has entered into...
Kangtai Biological Expands Global Reach with Varicella Vaccine Licensing Deals
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a China-based biopharmaceutical company, has entered into...
Kangtai Biological Partners with Indian Pharmaceutical Giant for 13-Valent Pneumonia Vaccine
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese biopharmaceutical company, has entered...
Shenzhen Kangtai Biological Partners with Saudi Importer for Pneumonia Vaccine Distribution
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with...
Shenzhen Kangtai Biological Partners with Biotis for 13-Valent Pneumococcal Vaccine in Indonesia
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has struck a partnership with Indonesian...
Kangtai Bio Partners with AstraZeneca and Combiphar to Expand Vaccine Collaboration
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered...
Kangtai Biological Partners with Pakistani Firm for Pneumonia Vaccine Expansion
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with...
Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment...